Developer docs
API playgroundTry for free, no card

Search company profiles

Porsolt

Full company profile

uuid000cipm

Namestring
Porsolt
Legal namestring
Porsolt SAS
Websiteurl
porsolt.com
Company typeenum
Private
Founded yearint
1985
Descriptiontext

Porsolt SAS is a privately held French preclinical contract research organization (CRO) founded in 1985 and headquartered in Le Genest-Saint-Isle, France. The company provides drug discovery, efficacy evaluation, safety pharmacology, and toxicology services to pharmaceutical companies, biotechnology firms, academic institutions, foundations, and not-for-profits, working with hundreds of clients worldwide and performing hundreds of studies annually. It operates over 70,000 square feet of purpose-built laboratory space, holds continuous GLP A-Grade compliance (maintained since 2000) and AAALAC International accreditation, and serves as a one-stop shop across the preclinical drug development workflow.

Its service portfolio spans more than 15 therapeutic areas (cardiovascular, CNS, dermatology, GI, inflammation, liver, oncology, obesity/metabolic, pain, respiratory, thrombosis, urogenital) and core platforms including in vivo and in vitro pharmacology, drug discovery services, general toxicology, predictive toxicity, pharmacokinetics, safety regulatory packages, and medical device testing. Supporting capabilities include preclinical formulation analysis, biomarker assays (ELISA, HTRF, flow cytometry, multiplexed detection), cell and tissue banking (including hiPSC-derived cells and proprietary biosensors), and quantitative image processing. The technical stack comprises HPLC, FLIPR Tetra high-throughput cellular screening, high-content and live-content imaging, automated flow cytometry, in vivo telemetry systems, and multimodal in vivo imaging. More than 30% of staff hold postgraduate qualifications, with over 150 years of combined scientific experience and more than 35 years of institutional memory.

Porsolt operates a B2B project-based services model, generating revenue from customized preclinical study contracts. Pricing is quote-based and not publicly disclosed. Its go-to-market relies on direct enterprise sales through international offices and local representatives, with a scientist-to-scientist engagement model providing clients direct access to scientific experts. The company has no disclosed funding rounds, no parent company, and no M&A activity, operating as an independent standalone entity. Its primary named external partnership is a supply agreement with the French Blood Bank for fresh donor blood used in preclinical assays.

Short descriptiontext

Porsolt SAS is a privately held French preclinical CRO founded in 1985, providing drug discovery, efficacy evaluation, and safety pharmacology services to pharmaceutical, biotechnology, academic, and non-profit clients across 15-plus therapeutic areas.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLe Genest, France
HQ citystring
Le Genest
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical CRO services, drug discovery research, safety pharmacology studies, efficacy evaluation services, toxicology testing services
Industry5 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAB
Safety Pharmacology (Cardio/CNS/Respiratory)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

Porsolt generates revenue through preclinical contract research organization services including drug discovery, screening, efficacy evaluation, and safety testing. Services span in vitro, in vivo, and ex vivo models across multiple therapeutic areas. Revenue is project-based, with studies tailored to client specifications across early screening through regulatory submission phases.

porsolt.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Porsolt is a preclinical Contract Research Organization (CRO) that delivers drug discovery, screening, efficacy evaluation, and safety pharmacology services to pharmaceutical, biotechnology, academic, and non-profit clients. Its work spans in vitro, in ovo, ex vivo, and in vivo models across 15+ therapeutic areas (cardiovascular, CNS, dermatology, GI, inflammation, liver, oncology, obesity/metabolic, pain, respiratory, thrombosis, urogenital) and is supported by pharmacokinetics, predictive toxicity, general toxicology, medical device testing, formulation analysis, biomarker assays, cell and tissue banking, and image-processing capabilities executed in GLP-compliant, AAALAC-accredited laboratories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Maintained GLP A-Grade status continuously for more than 20 years
+2 more records
Product overview1 text field

Porsolt is a global preclinical Contract Research Organization (CRO) established in 1985, providing comprehensive drug discovery and development services. The company offers a unified portfolio of therapeutic area-specific services (cardiovascular, CNS, dermatology, GI, inflammation, liver, oncology, obesity/metabolic, pain, respiratory, thrombosis, urogenital) combined with core preclinical service platforms including in vivo pharmacology, in vitro pharmacology, drug discovery services, general toxicology, in vitro toxicity testing, and predictive toxicity. Supporting services include pharmacokinetics, safety regulatory package (GLP), medical device testing, formulation analysis, biomarker assays, cell & tissue banks, and image processing & data analysis. Porsolt operates over 70,000 sq ft of laboratory facility space with GLP compliance and AAALAC accreditation.

Product and service25 records
1Cardiovascular System Services
CategoryTherapeutic Area Service
Description

Preclinical cardiovascular research services including models for assessing compound effects on the cardiovascular system, delivered for pharmaceutical and biotech sponsors.

2Central Nervous System Services
CategoryTherapeutic Area Service
Description

Preclinical CNS research services covering neurological disorder models and CNS drug development studies for pharma, biotech, and academic clients.

3Dermatology Services
CategoryTherapeutic Area Service
Description

Preclinical dermatology research services for skin conditions and dermatological therapeutics, executed through in vivo and in vitro models.

4Gastro-Intestinal System Services
CategoryTherapeutic Area Service
Description

Preclinical GI research services including models for gastrointestinal motility, emesis, and intestinal disorders, run for drug development sponsors.

5Inflammation Services
CategoryTherapeutic Area Service
Description

Preclinical inflammation research using in vivo and in vitro models for inflammatory disease drug development.

6Liver & Hepatic System Services
CategoryTherapeutic Area Service
Description

Preclinical liver research including hepatotoxicity models, liver fibrosis, and hepatic function assessment for safety and efficacy programs.

7Oncology Services
CategoryTherapeutic Area Service
Description

Preclinical oncology research including tumor models, immuno-oncology, and cancer therapeutic assessment studies.

8Obesity & Metabolic Disorder Services
CategoryTherapeutic Area Service
Description

Preclinical research for obesity, diabetes, and metabolic disorders using animal models and bioanalysis.

9Pain Services
CategoryTherapeutic Area Service
Description

Preclinical pain research models including acute, inflammatory, neuropathic, and chronic pain models for analgesic development.

10Respiratory System Services
CategoryTherapeutic Area Service
Description

Preclinical respiratory research including asthma, cough, fibrosis, and bronchospasm models for respiratory drug development.

11Thrombosis Services
CategoryTherapeutic Area Service
Description

Preclinical thrombosis research including arterial and venous thrombosis models and deep vein thrombosis assessment.

12Urogenital System Services
CategoryTherapeutic Area Service
Description

Preclinical urogenital research including bladder function, renal function, and genital system models.

13Medical Device Testing Services
CategorySpecialized Testing Service
Description

Preclinical medical device testing including cytotoxicity, genotoxicity, irritation, skin sensitization, and toxicity assessments.

14In Vivo Pharmacology
CategoryCore Service
Description

In vivo preclinical studies using living organisms to assess compound efficacy and safety across therapeutic areas, executed under GLP, AAALAC, and OECD guidelines.

15In Vitro Pharmacology
CategoryCore Service
Description

In vitro preclinical studies using isolated cells, tissues, and assays for compound screening and mechanism studies.

16Drug Discovery Services
CategoryCore Service
Description

Comprehensive drug discovery and development services including high-throughput screening, in vitro and in vivo pharmacology, toxicology, pharmacokinetics, ADME-Tox, and formulation development across therapeutic areas.

17General Toxicology Studies
CategoryDrug Development Service
Description

General toxicology studies including acute, chronic, and dose-finding toxicology assessments executed under GLP conditions.

18In Vitro Toxicity Testing
CategoryDrug Development Service
Description

In vitro toxicity testing including cytotoxicity assays, genotoxicity tests, and organ-specific toxicity evaluation.

19Predictive Toxicity Services
CategoryDrug Development Service
Description

Predictive toxicity testing including cardiotoxicity, hepatotoxicity, neurotoxicity, and nephrotoxicity assessments.

20Pharmacokinetics Services
CategoryDrug Development Service
Description

Preclinical pharmacokinetic studies analyzing ADME (absorption, distribution, metabolism, excretion) properties in multiple species.

21Safety Regulatory Package
CategoryDrug Development Service
Description

GLP-compliant safety pharmacology studies including behavioral pharmacology, core battery ICH S7, and supplemental studies supporting regulatory submissions.

22Preclinical Formulation Analysis
CategorySupporting Service
Description

Formulation analysis services including method development, validation, stability evaluation, and homogeneity testing for preclinical dosing formulations.

23Biomarker Assays
CategoryAnalytical Service
Description

Biomarker detection and analysis including clinical chemistry, coagulation, hematology, and immunoassays (ELISA, HTRF, flow cytometry, multiplexed detection).

24Cell & Tissue Banks
CategoryBiological Sample Service
Description

Access to cell lines, primary cell cultures (rodent and human), human iPSC-derived cells, cancer cell lines, proprietary biosensors, artificial 3D microtissues, and human/animal tissue samples for preclinical research.

25Image Processing & Data Analysis
CategoryAnalytical Service
Description

Quantitative image analysis and data processing for histology, immunohistochemistry, immunofluorescence, high-content imaging, and neuronal biology feature extraction.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Supply agreement for fresh blood from healthy donors used in preclinical research studies. This partnership provides essential biological materials for in vitro and ex vivo assay development and execution.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Preclinical CRO specializing in oncology and metabolic disease in vivo models; directly comparable to Porsolt's oncology and obesity/metabolic disorder service lines.

TypeDirect peer
Description

U.S.-based preclinical CRO focused on safety assessment, toxicology, and research models; directly competes with Porsolt on GLP toxicology and in vivo pharmacology for pharma/biotech sponsors.

TypeDirect peer
Description

European-headquartered contract research provider offering preclinical in vitro and in vivo pharmacology, safety, and DMPK services to pharma and biotech clients; highly comparable service mix and customer profile to Porsolt.

TypeBroad incumbent
Description

Global CRO with the largest preclinical and safety assessment franchise; competes directly with Porsolt in safety pharmacology, general toxicology, and in vivo efficacy studies across many of the same therapeutic areas.

TypeBroad incumbent
Description

Large bioanalytical and preclinical testing group; competes with Porsolt in bioanalysis, biomarker assays, and selected in vitro/in vivo safety work for pharma clients.

TypeBroad incumbent
Description

Global CRO/CDMO with extensive preclinical capabilities spanning DMPK, safety pharmacology, and in vivo models; serves the same pharma/biotech customer base with broader geographic reach.

TypeBroad incumbent
Description

Global CRO with preclinical and clinical offerings; competes with Porsolt on early-phase safety and translational pharmacology, especially for integrated programs.

TypeBroad incumbent
Description

One of the largest global CROs offering end-to-end preclinical and clinical services; competes with Porsolt for safety pharmacology and toxicology work, particularly from large pharma accounts.

TypeDirect peer
Description

Integrated CRO/CDMO offering preclinical drug discovery, in vitro/in vivo pharmacology, DMPK, and safety assessment globally; overlaps with Porsolt's efficacy, safety, and pharmacokinetics service lines.

TypeEmerging player
Description

Mid-sized preclinical CRO with capabilities in biologics safety and analytical services; an emerging alternative for sponsors seeking smaller, science-driven preclinical partners comparable to Porsolt.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Porsolt

Preclinical Contract Research Servicesporsolt.com

Porsolt SAS is a privately held French preclinical CRO founded in 1985, providing drug discovery, efficacy evaluation, and safety pharmacology services to pharmaceutical, biotechnology, academic, and non-profit clients across 15-plus therapeutic areas.

What Porsolt does

Porsolt SAS is a privately held French preclinical contract research organization (CRO) founded in 1985 and headquartered in Le Genest-Saint-Isle, France. The company provides drug discovery, efficacy evaluation, safety pharmacology, and toxicology services to pharmaceutical companies, biotechnology firms, academic institutions, foundations, and not-for-profits, working with hundreds of clients worldwide and performing hundreds of studies annually. It operates over 70,000 square feet of purpose-built laboratory space, holds continuous GLP A-Grade compliance (maintained since 2000) and AAALAC International accreditation, and serves as a one-stop shop across the preclinical drug development workflow.

Its service portfolio spans more than 15 therapeutic areas (cardiovascular, CNS, dermatology, GI, inflammation, liver, oncology, obesity/metabolic, pain, respiratory, thrombosis, urogenital) and core platforms including in vivo and in vitro pharmacology, drug discovery services, general toxicology, predictive toxicity, pharmacokinetics, safety regulatory packages, and medical device testing. Supporting capabilities include preclinical formulation analysis, biomarker assays (ELISA, HTRF, flow cytometry, multiplexed detection), cell and tissue banking (including hiPSC-derived cells and proprietary biosensors), and quantitative image processing. The technical stack comprises HPLC, FLIPR Tetra high-throughput cellular screening, high-content and live-content imaging, automated flow cytometry, in vivo telemetry systems, and multimodal in vivo imaging. More than 30% of staff hold postgraduate qualifications, with over 150 years of combined scientific experience and more than 35 years of institutional memory.

Porsolt operates a B2B project-based services model, generating revenue from customized preclinical study contracts. Pricing is quote-based and not publicly disclosed. Its go-to-market relies on direct enterprise sales through international offices and local representatives, with a scientist-to-scientist engagement model providing clients direct access to scientific experts. The company has no disclosed funding rounds, no parent company, and no M&A activity, operating as an independent standalone entity. Its primary named external partnership is a supply agreement with the French Blood Bank for fresh donor blood used in preclinical assays.

Porsolt firmographics

Firmographics
Name
Porsolt
Legal name
Porsolt SAS
Website
https://porsolt.com
Company type
Private
Founded year
1985
Operating status
Operating
Headcount range
51–100 employees
Short description
Porsolt SAS is a privately held French preclinical CRO founded in 1985, providing drug discovery, efficacy evaluation, and safety pharmacology services to pharmaceutical, biotechnology, academic, and non-profit clients across 15-plus therapeutic areas.
Ownership category
akta.pro rank

Porsolt industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAB
Safety Pharmacology (Cardio/CNS/Respiratory)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAC
DMPK / ADME & Bioanalysis
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Preclinical CRO services
  • Drug discovery research
  • Safety pharmacology studies
  • Efficacy evaluation services
  • Toxicology testing services

Where Porsolt is headquartered

Location

Headquarters

HQ city
Le Genest
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Porsolt business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: Porsolt generates revenue through preclinical contract research organization services including drug discovery, screening, efficacy evaluation, and safety testing. Services span in vitro, in vivo, and ex vivo models across multiple therapeutic areas. Revenue is project-based, with studies tailored to client specifications across early screening through regulatory submission phases.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Porsolt product offering

Product offering

Core offering

Porsolt is a preclinical Contract Research Organization (CRO) that delivers drug discovery, screening, efficacy evaluation, and safety pharmacology services to pharmaceutical, biotechnology, academic, and non-profit clients. Its work spans in vitro, in ovo, ex vivo, and in vivo models across 15+ therapeutic areas (cardiovascular, CNS, dermatology, GI, inflammation, liver, oncology, obesity/metabolic, pain, respiratory, thrombosis, urogenital) and is supported by pharmacokinetics, predictive toxicity, general toxicology, medical device testing, formulation analysis, biomarker assays, cell and tissue banking, and image-processing capabilities executed in GLP-compliant, AAALAC-accredited laboratories.

Product overview

Porsolt is a global preclinical Contract Research Organization (CRO) established in 1985, providing comprehensive drug discovery and development services. The company offers a unified portfolio of therapeutic area-specific services (cardiovascular, CNS, dermatology, GI, inflammation, liver, oncology, obesity/metabolic, pain, respiratory, thrombosis, urogenital) combined with core preclinical service platforms including in vivo pharmacology, in vitro pharmacology, drug discovery services, general toxicology, in vitro toxicity testing, and predictive toxicity. Supporting services include pharmacokinetics, safety regulatory package (GLP), medical device testing, formulation analysis, biomarker assays, cell & tissue banks, and image processing & data analysis. Porsolt operates over 70,000 sq ft of laboratory facility space with GLP compliance and AAALAC accreditation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cardiovascular System Services Preclinical cardiovascular research services including models for assessing compound effects on the cardiovascular system, delivered for pharmaceutical and biotech sponsors.
  • Central Nervous System Services Preclinical CNS research services covering neurological disorder models and CNS drug development studies for pharma, biotech, and academic clients.
  • Dermatology Services Preclinical dermatology research services for skin conditions and dermatological therapeutics, executed through in vivo and in vitro models.
  • Gastro-Intestinal System Services Preclinical GI research services including models for gastrointestinal motility, emesis, and intestinal disorders, run for drug development sponsors.
  • Inflammation Services Preclinical inflammation research using in vivo and in vitro models for inflammatory disease drug development.
  • Liver & Hepatic System Services Preclinical liver research including hepatotoxicity models, liver fibrosis, and hepatic function assessment for safety and efficacy programs.
  • Oncology Services Preclinical oncology research including tumor models, immuno-oncology, and cancer therapeutic assessment studies.
  • Obesity & Metabolic Disorder Services Preclinical research for obesity, diabetes, and metabolic disorders using animal models and bioanalysis.
  • Pain Services Preclinical pain research models including acute, inflammatory, neuropathic, and chronic pain models for analgesic development.
  • Respiratory System Services Preclinical respiratory research including asthma, cough, fibrosis, and bronchospasm models for respiratory drug development.
  • Thrombosis Services Preclinical thrombosis research including arterial and venous thrombosis models and deep vein thrombosis assessment.
  • Urogenital System Services Preclinical urogenital research including bladder function, renal function, and genital system models.
  • Medical Device Testing Services Preclinical medical device testing including cytotoxicity, genotoxicity, irritation, skin sensitization, and toxicity assessments.
  • In Vivo Pharmacology In vivo preclinical studies using living organisms to assess compound efficacy and safety across therapeutic areas, executed under GLP, AAALAC, and OECD guidelines.
  • In Vitro Pharmacology In vitro preclinical studies using isolated cells, tissues, and assays for compound screening and mechanism studies.
  • Drug Discovery Services Comprehensive drug discovery and development services including high-throughput screening, in vitro and in vivo pharmacology, toxicology, pharmacokinetics, ADME-Tox, and formulation development across therapeutic areas.
  • General Toxicology Studies General toxicology studies including acute, chronic, and dose-finding toxicology assessments executed under GLP conditions.
  • In Vitro Toxicity Testing In vitro toxicity testing including cytotoxicity assays, genotoxicity tests, and organ-specific toxicity evaluation.
  • Predictive Toxicity Services Predictive toxicity testing including cardiotoxicity, hepatotoxicity, neurotoxicity, and nephrotoxicity assessments.
  • Pharmacokinetics Services Preclinical pharmacokinetic studies analyzing ADME (absorption, distribution, metabolism, excretion) properties in multiple species.
  • Safety Regulatory Package GLP-compliant safety pharmacology studies including behavioral pharmacology, core battery ICH S7, and supplemental studies supporting regulatory submissions.
  • Preclinical Formulation Analysis Formulation analysis services including method development, validation, stability evaluation, and homogeneity testing for preclinical dosing formulations.
  • Biomarker Assays Biomarker detection and analysis including clinical chemistry, coagulation, hematology, and immunoassays (ELISA, HTRF, flow cytometry, multiplexed detection).
  • Cell & Tissue Banks Access to cell lines, primary cell cultures (rodent and human), human iPSC-derived cells, cancer cell lines, proprietary biosensors, artificial 3D microtissues, and human/animal tissue samples for preclinical research.
  • Image Processing & Data Analysis Quantitative image analysis and data processing for histology, immunohistochemistry, immunofluorescence, high-content imaging, and neuronal biology feature extraction.

Quantifiable outcome

  • Maintained GLP A-Grade status continuously for more than 20 years
  • +2 more outcomes

Companies that use Porsolt

Customer profile

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Porsolt technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Porsolt partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • French Blood BankcoreStrategic or Co-development PartnerSupply agreement for fresh blood from healthy donors used in preclinical research studies. This partnership provides essential biological materials for in vitro and ex vivo assay development and execution.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Porsolt competitors and assessment

Company assessment

Direct peers

  • Crown Bioscience: Preclinical CRO specializing in oncology and metabolic disease in vivo models; directly comparable to Porsolt's oncology and obesity/metabolic disorder service lines.
  • Inotiv: U.S.-based preclinical CRO focused on safety assessment, toxicology, and research models; directly competes with Porsolt on GLP toxicology and in vivo pharmacology for pharma/biotech sponsors.
  • Evotec: European-headquartered contract research provider offering preclinical in vitro and in vivo pharmacology, safety, and DMPK services to pharma and biotech clients; highly comparable service mix and customer profile to Porsolt.
  • Pharmaron: Integrated CRO/CDMO offering preclinical drug discovery, in vitro/in vivo pharmacology, DMPK, and safety assessment globally; overlaps with Porsolt's efficacy, safety, and pharmacokinetics service lines.

Broad incumbents

  • Charles River Laboratories: Global CRO with the largest preclinical and safety assessment franchise; competes directly with Porsolt in safety pharmacology, general toxicology, and in vivo efficacy studies across many of the same therapeutic areas.
  • Eurofins Scientific: Large bioanalytical and preclinical testing group; competes with Porsolt in bioanalysis, biomarker assays, and selected in vitro/in vivo safety work for pharma clients.
  • WuXi AppTec: Global CRO/CDMO with extensive preclinical capabilities spanning DMPK, safety pharmacology, and in vivo models; serves the same pharma/biotech customer base with broader geographic reach.
  • ICON plc: Global CRO with preclinical and clinical offerings; competes with Porsolt on early-phase safety and translational pharmacology, especially for integrated programs.
  • Labcorp Drug Development (formerly Covance): One of the largest global CROs offering end-to-end preclinical and clinical services; competes with Porsolt for safety pharmacology and toxicology work, particularly from large pharma accounts.

Emerging players

  • Bionova Scientific: Mid-sized preclinical CRO with capabilities in biologics safety and analytical services; an emerging alternative for sponsors seeking smaller, science-driven preclinical partners comparable to Porsolt.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Porsolt social profiles

Digital presence

Porsolt compliance and trust

Trust signal

Compliance2 records

Porsolt financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Porsolt leadership team

Management profile

Number of profiles

Profiles2 records

Porsolt funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Porsolt M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Porsolt

What does Porsolt do?

Porsolt is a preclinical Contract Research Organization (CRO) that delivers drug discovery, screening, efficacy evaluation, and safety pharmacology services to pharmaceutical, biotechnology, academic, and non-profit clients. Its work spans in vitro, in ovo, ex vivo, and in vivo models across 15+ therapeutic areas (cardiovascular, CNS, dermatology, GI, inflammation, liver, oncology, obesity/metabolic, pain, respiratory, thrombosis, urogenital) and is supported by pharmacokinetics, predictive toxicity, general toxicology, medical device testing, formulation analysis, biomarker assays, cell and tissue banking, and image-processing capabilities executed in GLP-compliant, AAALAC-accredited laboratories.

Is Porsolt a public or private company?

Porsolt is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Porsolt founded?

Porsolt was founded in 1985. It employs 51 to 100 people.

Where is Porsolt based?

Porsolt is headquartered in Le Genest, France, in the Europe region.

How does Porsolt make money?

One revenue line is on record: contract Research Services.

Who are Porsolt's main competitors?

Direct peers on record are Crown Bioscience, Inotiv, Evotec and Pharmaron. Broad incumbents are Charles River Laboratories, Eurofins Scientific, WuXi AppTec, ICON plc and Labcorp Drug Development (formerly Covance). Bionova Scientific is listed as an emerging player.

Does Porsolt have an API?

No public API is recorded for Porsolt.

What industry is Porsolt in?

Porsolt's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAFAA, In Vivo Pharmacology (Efficacy/PD Models). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PorsoltDrug Discovery ServicesPorsolt offers comprehensive drug discovery and development services, leveraging its 40-year history in preclinical research to support pharmaceutical companies, biotechnology firms, and academic institutions. The company provides specialized capabilities including high-throughput screening, in vitro and in vivo pharmacology, toxicology, and biomarker discovery across various therapeutic areas.LoomlyApax takes big stake in French CRO Porsolt, expects to grow staff 40% in 4 yearsApax Partners took a majority stake in French CRO Porsolt, which has about 100 employees and 40 years of preclinical services. Apax expects to grow Porsolt's staff by up to 40% over four years and use the investment to expand globally. Financial terms were not disclosed.PR NewswireApax Partners acquires a majority stake in Porsolt to support its growth strategy to become a global leader in preclinical services.Apax Partners has acquired a majority stake in Porsolt, a global Contract Research Organization (CRO), to accelerate its growth strategy. The investment will support Porsolt's expansion into new therapeutic areas and its goal of increasing staff by 40% over the next four years. This move aims to enhance Porsolt's capabilities in drug screening, efficacy, and safety testing for worldwide clients.Les EchosPorsolt s’offre un buy-out avec Apax PartnersPorsolt has structured a buy-out (OBO) with Apax Partners, who is taking a majority stake in the company. Founders Guillaume Froget and David Pushett, who previously held 100% of the capital, will retain minority positions.BioSpaceApax Partners acquires a majority stake in Porsolt to support its growth strategy to become a global leader in preclinical services.Apax Partners has acquired a majority stake in Porsolt, an international Contract Research Organization (CRO), to support its growth strategy. The investment will enable Porsolt to accelerate hiring by 40% over the next four years and expand its global footprint through bolt-on acquisitions in Europe and the US.PR NewswireAgrandissement du centre de recherche de Porsolt : l'organisme développe ses services de découverte de médicamentsPorsolt SAS has completed a 511-square-meter expansion of its research center in Laval, France, to enhance its preclinical drug discovery capabilities. This growth allows the organization to integrate advanced technologies and expanded in vitro and ex vivo testing services for the pharmaceutical and biotechnology sectors.PR NewswirePorsolt aumenta su capacidad en el servicio de descubrimiento de fármacos con la reciente expansión de sus instalaciones de investigaciónPorsolt SAS, a preclinical contract research organization based in Le Genest-Saint-Isle, France, has completed a major expansion of its research facilities, adding 500 m² of experimental space. The expansion incorporates new research areas, cutting-edge technologies from Fluofarma including IVF laboratories, cell cultures, flow cytometry, and histology, as well as expanded capabilities in chemistry, biochemistry, biomarkers, and in vivo studies. The company stated the expansion reflects its steady growth and enables it to better serve its growing global client base of pharmaceutical and biotech companies.PR NewswirePorsolt Increases Its Drug Discovery Service Capabilities With the Recent Expansion of Its Research FacilityPorsolt SAS, a preclinical screening, efficacy, and safety contract research organization, has completed a significant expansion of its research facility in Laval, France, adding 5,500 sq.ft. of experimental space. The expansion integrates new in vitro laboratories including cell culture, flow cytometry, histology, imaging, and analysis capabilities that were incorporated from Fluofarma, along with expanded chemistry, biochemistry, biomarker, and ex-vivo capabilities. The company stated this growth enables it to meet the needs of its expanding global client base and cover more stages in the drug discovery process.